HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shellock, F. G. Articles by Spinazzi, A. Search for Related Content PubMed PubMed Citation Articles by Shellock, F. G. Articles by Spinazzi, A. Social Bookmarking                      What's this? Hotlight (NEW!) What's Hotlight?

MRI Safety Update 2008: Part 1, MRI Contrast Agents and Nephrogenic Systemic Fibrosis

¹ Keck School of Medicine, University of Southern California and Institute for Magnetic Resonance Safety, Education, and Research, 7511 McConnell Ave., Los Angeles, CA 90045.
² Group Medical and Regulatory Affairs, Bracco Diagnostics, Inc., Princeton, NJ.

OBJECTIVE. This article is the first part of a two-part series on MRI safety. In this article, part 1, the topic of MRI contrast agents and nephrogenic systemic fibrosis (NSF) is addressed.

CONCLUSION. To prevent incidents and accidents associated with MRI, it is necessary to regularly revisit the safety topics that directly impact patient management especially with respect to the subjects that are "new" (e.g., MRI contrast agents and NSF), those that should be reassessed because of recent changes, topics that deserve emphasis because of controversy or confusion, and information that should be considered in light of new findings.

Keywords: 3-T MRI • devices • gadolinium-based contrast agents • implants • MRI artifacts • MRI contrast agents • MRI safety • nephrogenic systemic fibrosis

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. J. Kilner, T. Geva, H. Kaemmerer, P. T. Trindade, J. Schwitter, and G. D. Webb Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology Eur. Heart J., January 11, 2010; (2010) ehp586v1. [Abstract] [Full Text] [PDF]

				M. Y. Desai and S. D. Flamm End of the Road for Delayed Hyperenhancement Cardiac Magnetic Resonance? J. Am. Coll. Cardiol. Img., April 1, 2009; 2(4): 421 - 423. [Full Text] [PDF]

				V. M. Runge Gadolinium and Nephrogenic Systemic Fibrosis Am. J. Roentgenol., April 1, 2009; 192(4): W195 - W196. [Full Text] [PDF]

				J. L. Zhang, H. Rusinek, L. Bokacheva, R. P. Lim, Q. Chen, P. Storey, K. Prince, E. M. Hecht, D. C. Kim, and V. S. Lee Angiotensin-converting enzyme inhibitor-enhanced MR renography: repeated measures of GFR and RPF in hypertensive patients Am J Physiol Renal Physiol, April 1, 2009; 296(4): F884 - F891. [Abstract] [Full Text] [PDF]

				E. Ritz and A. Remppis CHAPTER 15b Cardiovascular Problems in Chronic Kidney Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text]

				P. M. Colletti Nephrogenic Systemic Fibrosis and Gadolinium: A Perfect Storm Am. J. Roentgenol., October 1, 2008; 191(4): 1150 - 1153. [Full Text] [PDF]